Home  >  News
Msc_Apr22 Advertisement
6Sugar_Free_Sweetener.gif
you can get e-magazine links on WhatsApp. Click here
Marketing + Font Resize -

Mankind Pharma and BDR Pharma to launch anti Covid-19 pill Molulife

Our Bureau, Mumbai
Wednesday, December 29, 2021, 16:45 Hrs  [IST]

Taking a significant step towards countering Covid-19 in India, drug major Mankind Pharma and leading generic pharmaceutical company BDR Pharmaceuticals launches oral anti-Covid pill Molulife (molnupiravir).

The tie-up is a licensing arrangement where production is by BDR Pharma and marketing, selling, promotion, distribution is by Mankind Pharma.

Molnupiravir, is an anti-viral drug developed by Merck & Co (known as MSD outside US), Inc. in collaboration with Ridgeback Biotherapeutics. It is the first oral anti-Covid pill approved by the UK’s drug regulator-UK Medicines and Healthcare Products Regulatory Agency (MHRA) for the treatment of mild-to-moderate Covid-19 in adults. On 23rd December, 2021, US Food and Drug Administration issued an emergency use authorization (EUA) for molnupiravir for the treatment of mild-to-moderate coronavirus disease (Covid-19) in adults with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe Covid-19, including hospitalization or death, and for whom alternative Covid-19 treatment options authorized by the FDA are not accessible or clinically appropriate.

Post the US FDA nod, the Indian Drug Regulator, Drugs Controller General of India (DCGI) granted permission for restricted use of molnupiravir under emergency situation for treatment of adult patients with SpO2 93% and who have high risk of progression of the disease.

Molnupiraviris an orally administered form of a potent ribonucleoside analog that inhibits the replication of SARS-CoV-2, the causative agent of Covid-19. Molnupiravir targets the SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) the same way other nucleoside analogues do and mediates replication and transcription of the coronavirus genome.

Raheel Shah, director – business development, BDR Pharma said, “This launch further enhances the Covid-19 treatment portfolio in BDR’s product basket with the addition of generic molnupiravir. We are pleased to collaborate with Mankind Pharma to take one step forward in fighting the virus. At this point of time, the nation needs such drugs that can effectively help in fighting the cases.”

With the nod, Mankind Pharma known for its affordable medicines in partnership with BDR Pharma, plans to make Molulife available at mass scale in India to strengthen the Covid-19 fight in the country.

Dr. Sanjay Koul, Senior president, sales & marketing, MankindPharma said, “A pill for Covid-19 is bound to go miles in strengthening defense against Covid-19 battle. Mankind with its motto ‘serving life’- will make Molulife available in every nook and corner of the country. The company focusing on providing a range of medicines for the management and treatment of Covid-19 in India.”

 

*POST YOUR COMMENT
Comments
* Name :     
* Email :    
  Website :  
   
     
 
 
 
Copyright © 2016 Saffron Media Pvt. Ltd |